GENA LEATZOW: Open Payments
NPI 1174001747 · RESTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,062 in 35 payments from 8 companies in 2025. Trend: 2023 $767 · 2024 $814 · 2025 $1,062
Food & beverage: $810Long term medical supply or device loan: $252
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $338 |
| Integra LifeSciences Corporation | 2 | $252 |
| Optinose US, Inc. | 12 | $177 |
| Regeneron Healthcare Solutions, Inc. | 5 | $120 |
| Stryker Corporation | 2 | $67 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| Merck Sharp & Dohme LLC | 1 | $21 |
Products named: DUPIXENT, XHANCE, Integra, MicroMatrix, AUDION ET DILATION SYSTEM, NUCALA, LIBTAYO, KEYTRUDA QLEX.
Industry payments across VA — which companies pay providers there.
